Collegium Pharmaceutical (NASDAQ:COLL) had its price objective increased by investment analysts at Jefferies Group to $32.00 in a report released on Monday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s price objective points to a potential upside of 31.31% from the company’s previous close. Jefferies Group also issued estimates for Collegium Pharmaceutical’s FY2020 earnings at $1.11 EPS.

A number of other research analysts have also recently issued reports on the stock. BidaskClub cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 9th. Needham & Company LLC boosted their price objective on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Piper Jaffray Companies restated a “buy” rating and set a $24.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, December 7th. Finally, Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Monday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $27.17.

Collegium Pharmaceutical (NASDAQ:COLL) opened at $24.37 on Monday. The stock has a market cap of $793.54 and a P/E ratio of -8.21. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $26.77.

In other Collegium Pharmaceutical news, CTO Alison B. Fleming sold 4,029 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the transaction, the chief technology officer now owns 28,513 shares of the company’s stock, valued at $484,721. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $17.34, for a total transaction of $17,340,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,055,558 shares of company stock worth $18,570,177. Insiders own 25.76% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in COLL. Voya Investment Management LLC bought a new position in Collegium Pharmaceutical in the second quarter valued at approximately $125,000. Benjamin F. Edwards & Company Inc. lifted its stake in Collegium Pharmaceutical by 87.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares in the last quarter. Nationwide Fund Advisors lifted its stake in Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares in the last quarter. Acadian Asset Management LLC bought a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $176,000. Finally, JPMorgan Chase & Co. bought a new position in Collegium Pharmaceutical in the third quarter valued at approximately $192,000. 82.40% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group Boosts Collegium Pharmaceutical (COLL) Price Target to $32.00” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/02/14/jefferies-group-boosts-collegium-pharmaceutical-coll-price-target-to-32-00.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.